Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab in Castration-Resistant Prostate Cancer
NCT00058539Phase 2Completed
- Sponsor
- Genentech
- Start
- Apr 2003
- Primary completion
- Oct 2004
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of pertuzumab in prostate cancer (PCa), sponsored by Genentech. Primary endpoints: Objective Response Rate, Prostate Specific Antigen Response Rate and 1 more. Started Apr 2003; status: completed.
02
Drugs
pertuzumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00058539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00058539.